Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.67 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.67 |
| ▸ | RARB | P10826 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | RARA | P10276 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303752 | 1.00 | GRIN2D (0.67) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL7342564 | 1.00 | GRIN2D (0.67) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL7331987 | 1.00 | GRIN2D (0.67) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| Hydrochloric Acid SCHEMBL10716592 | 0.98 | GRIN2D (0.65) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL10081274 | 0.98 | GRIN2D (0.68) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL11071411 | 0.94 | GRIN2D (0.70) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL17592174 | 0.87 | GRIN2D (0.65) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL8152604 | 0.86 | THRA (0.55) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL10600377 | 0.86 | THRA (0.55) | GRIN2DGRIN2AGRIN2BGRIN2CRARB | |
| SCHEMBL18917571 | 0.86 | GRIN2D (0.64) | GRIN2DGRIN2AGRIN2BGRIN2CRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244929-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. | 2013-09-19 | — | — | US | disclosed |
| CN-102939095-A | Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials | MERCK SHARP & DOHME | 2013-02-20 | — | — | CN | disclosed |
| EP-2544702-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112441-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-5356561-A | Carboxylate compounds, liquid crystal compositions and liquid crystal elements containing said compounds and method of optical modulation using said elements | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244929-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | SPPL2B, ENGASE, PEPD | GRIN2D 3767/4885GRIN2A 3504/4885GRIN2B 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.